RECRUITINGINTERVENTIONAL
Safely Reduce Cystoscopic Evaluations for Hematuria Patients
About This Trial
The SeARCH-trial assess the clinical impact of a molecular urine test as a 'urine-first' strategy in the diagnostic workup of patients presenting with microscopic hematuria.
Who May Be Eligible (Plain English)
Who May Qualify:
- Microscopically confirmed microscopic hematuria of voided urine defined as ≥3 erythrocytes per high power field
- Male patients ≥40 years
- Female patients ≥50 years
Who Should NOT Join This Trial:
- History of urothelial bladder- or urinary tract cancer
- Presence of macroscopic (visible) hematuria
- Woman who is or may be pregnant
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Microscopically confirmed microscopic hematuria of voided urine defined as ≥3 erythrocytes per high power field
* Male patients ≥40 years
* Female patients ≥50 years
Exclusion Criteria:
* History of urothelial bladder- or urinary tract cancer
* Presence of macroscopic (visible) hematuria
* Woman who is or may be pregnant
Treatments Being Tested
DIAGNOSTIC_TEST
urine-first strategy
Only patients with an abnormal urine test result undergo a diagnostic workup, i.e. cystoscopy and upper-tract imaging.
Locations (1)
SeARCH-trial Pijpers
Rotterdam, Netherlands